Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952504 | 0.90 | CA1 (0.44) | CYP3A4TSHRNFKB1NPSR1CA1 | |
| SCHEMBL5153152 | 0.86 | TSHR (0.37) | CYP3A4TSHRNFKB1NPSR1CA1 | |
| SCHEMBL3464732 | 0.85 | CA1 (0.41) | CYP3A4TSHRNFKB1NPSR1CA1 | |
| SCHEMBL1230198 | 0.85 | CA1 (0.44) | CYP3A4TSHRNFKB1NPSR1CA1 | |
| SCHEMBL2950012 | 0.84 | CA2 (0.37) | CYP3A4TSHRNFKB1NPSR1CA1 | |
| SCHEMBL9332532 | 0.83 | CA1 (0.39) | CYP3A4TSHRNFKB1NPSR1CA1 | |
| SCHEMBL5488621 | 0.80 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL1230248 | 0.80 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL1229384 | 0.80 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL7631487 | 0.80 | CA1 (0.41) | CYP3A4TSHRNFKB1NPSR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8337788-B2 | Method for preparing a colloidal zirconia solution | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8142896-B2 | Optical article comprising a multilayer anti-reflective coating and method of production thereof | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20110228400-A1 | Method for Manufacturing an Optical Article with Anti-Glare Properties | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQU E) (FR) | 2011-09-22 | — | — | US | disclosed |
| US-20100144918-A1 | Method for Preparing a Colloidal Zirconia Solution | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100033824-A1 | Optical Article Comprising a Multilayer Anti-Reflective Coating and Method Of Production Thereof | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D'OPTIQUE (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20060275627-A1 | Optical article comprising a multilayer anti-reflective coating and method for production thereof | ESSILOR INTERNATIONAL COMPAGNIE GENERALE D' OPTIQU (FR) | 2006-12-07 | — | — | US | disclosed |
| EP-0051405-B1 | ANTI-FOGGING COATING FILM | TORAY INDUSTRIES, INC. (JP) | 1985-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144918-A1 | Method for Preparing a Colloidal Zirconia Solution | ZRANB2, NPM1, NAF1 | CYP3A4 3819/4885TSHR 1472/4885NFKB1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.